Ology Bioservices Inc., a biologics contract development and manufacturing organization (CDMO), has been awarded a contract by the U.S. Army Contracting Command, Aberdeen Proving Ground, Maryland. The contract ceiling value is $106.3 million, of which $53.1 million was obligated at the time of award.
In this program, Ology Bioservices will manage the reservation of production capacity of approximately 186,840,000 doses of critical vaccines and therapeutics for COVID-19. This work is in support of the Operation Warp Speed response to the ongoing pandemic.
“Along with producing vaccines and monoclonal antibodies to eventually combat the spread of COVID-19, the team at Ology Bioservices is very proud to support the fill and finishing network as needed by Operation Warp Speed,” said Peter H. Khoury, Ph.D., President and Chief Executive Officer of Ology Bioservices.